Literature DB >> 9097999

Epithelial cell folate depletion occurs in neoplastic but not adjacent normal colon mucosa.

J Meenan1, E O'Hallinan, J Scott, D G Weir.   

Abstract

BACKGROUND & AIMS: Restricted folate supply is associated with the development of carcinoma, and folate supplements have a protective effect in colorectal carcinoma. This effect may be mediated through correction of local folate deficiency. The aim of this study was to define the folate content of neoplastic colonic epithelial cells and its relation to that of adjacent normal tissue and circulating levels.
METHODS: Epithelial cells were isolated from endoscopic biopsy specimens of normal, adenocarcinoma, adenoma, and adjacent normal colonic mucosa by ion chelation. Intracellular folate levels were determined by microbiological assay.
RESULTS: Folate levels in carcinoma specimens were lower than in adjacent normal tissue (P < 0.02). Levels in adenoma epithelial cells were lower than in adjacent normal tissue, although this did not reach statistical significance (P < 0.06). Epithelial cells from normal tissue and mucosa adjacent to tumors and adenomata had similar folate contents. Blood folate and vitamin B12 indices for all groups were normal.
CONCLUSIONS: Malignant colon epithelial cells show a relative localized folate deficiency. However, there is no evidence for the occurrence of generalized mucosal folate deficiency. This finding suggests that folate supplements do not inhibit carcinogenesis through correction of localized folate depletion.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9097999     DOI: 10.1016/s0016-5085(97)70127-6

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  7 in total

1.  Mathematical modeling predicts the effect of folate deficiency and excess on cancer-related biomarkers.

Authors:  Marian L Neuhouser; H Frederik Nijhout; Jesse F Gregory; Michael C Reed; S Jill James; Amy Liu; Barry Shane; Cornelia M Ulrich
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-07-13       Impact factor: 4.254

2.  Red blood cell folate and plasma folate are not associated with risk of incident colorectal cancer in the Women's Health Initiative observational study.

Authors:  Marian L Neuhouser; Ting-Yuan David Cheng; Shirley A A Beresford; Elissa Brown; Xiaoling Song; Joshua W Miller; Yingye Zheng; Cynthia A Thomson; James M Shikany; Mara Z Vitolins; Thomas Rohan; Ralph Green; Cornelia M Ulrich
Journal:  Int J Cancer       Date:  2015-02-24       Impact factor: 7.396

3.  Concentration of folate in colorectal tissue biopsies predicts prevalence of adenomatous polyps.

Authors:  Andrew Flood; Joel B Mason; Zhenhua Liu; Brooks D Cash; Arthur Schatzkin; Philip S Schoenfeld; Amanda J Cross
Journal:  Gut       Date:  2010-11-10       Impact factor: 23.059

4.  Folic acid supplementation inhibits recurrence of colorectal adenomas: a randomized chemoprevention trial.

Authors:  Richard Jaszewski; Sabeena Misra; Martin Tobi; Nadeem Ullah; Jo Ann Naumoff; Omer Kucuk; Edi Levi; Bradley N Axelrod; Bhaumik B Patel; Adhip P N Majumdar
Journal:  World J Gastroenterol       Date:  2008-07-28       Impact factor: 5.742

5.  Systemic folate status, rectal mucosal folate concentration and dietary intake in patients at differential risk of bowel cancer (The FAB2 Study).

Authors:  Elizabeth A Williams; Mark Welfare; Alison Spiers; Marilyn H Hill; Wendy Bal; Eileen R Gibney; Yvonne Duckworth; Hilary J Powers; John C Mathers
Journal:  Eur J Nutr       Date:  2012-12-28       Impact factor: 5.614

6.  Folate deficiency-triggered redox pathways confer drug resistance in hepatocellular carcinoma.

Authors:  Chun-Te Ho; Hung-Sheng Shang; Jin-Biou Chang; Jun-Jen Liu; Tsan-Zon Liu
Journal:  Oncotarget       Date:  2015-09-22

7.  Detection of replicative integrity in small colonic biopsies using the BrdUrd comet assay.

Authors:  A P McGlynn; G R Wasson; S O'Reilly; V J McKelvey-Martin; H McNulty; J J Strain; G McKerr; F Mullan; N Mahmud; J Scott; D G Weir; C S Downes
Journal:  Br J Cancer       Date:  2003-03-24       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.